Last updated 16 days ago
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
400 patients around the world
Available in United States, Spain, Chile, Argentina
Seagen Inc.
13Research sites
400Patients around the world
This study is for people with
Colorectal cancer
Colon cancer
Rectal cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Británico de Buenos Aires - CABA
Recruiting
Centro Médico Privado CEMAIC - Córdoba
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Instituto Oncológico de Córdoba IONC - Fundación Richardet Longo
Recruiting
Hospital Nossa Senhora da Conceição
Recruiting
Oncocentro APYS - Valparaíso
Recruiting
Centro de Estudios Clínicos SAGA - CECSAGA
Recruiting
Hospital Universitario La Paz
Recruiting
Hospital Universitario 12 de Octubre
Recruiting
StudyMOUNTAINEER-03
SponsorSeagen Inc.
Study typeInterventional
Conditions
Colorectal cancerColon cancerRectal cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05253651
